CCCC

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights. “During the first quarter, we made strong progress advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for the treatment of multiple myeloma, highlighted by the initiation of two new clinical trials and plans to begin an additional combination trial next year. We believe our clinical development path further supports the advancement of IKZF1/3 degradation – the only mechanism targeting a central transcriptional dependency in multiple myeloma – and will help position cemsidomide as a potentially foundational therapy for these patients with relapsed refractory disease,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “In addition to these clinical advances, we also expanded our partnership with Roche through a new collaboration focused on degrader-antibody conjugates, broadening the reach of targeted protein degradation in cancer. Supported by a strong balance sheet through key value inflection points, we remain focused on advancing our portfolio to deliver the next generation of targeted protein degrader medicines to patients.” FIRST QUARTER 2026 HIGHLIGHTS AND RECENT ACHIEVEMENTS Planning is underway to initiate an additional Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma (MM) therapies. The trial will include two treatment arms: (1) cemsidomide, dexamethasone, and a proteasome inhibitor, and (2) cemsidomide, dexamethasone, and a CD38 antibody, for the relapsed refractory (RR) MM patients. Trial initiation is expected in the first half of 2027 with the goal of further establishing cemsidomide’s profile as a potentially foundational therapy across multiple lines of MM treatment. Data from the Phase 1 trial evaluating cemsidomide in combination with dexamethasone in RRMM was accepted as a poster presentation at the European Hematology Annual (EHA) Congress taking place from June 11 – June 14, 2026, in Stockholm, Sweden. Enrollment was completed in September 2025, and the poster presentation will include further analysis from the ongoing trial. A trial-in-progress...

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the year ended December 31, 2025, as well as business updates. “We made significant progress in 2025, notably demonstrating cemsidomide’s best-in-class potential, establishing an efficient and differentiated regulatory path for cemsidomide, and extending our cash runway beyond key value‑inflection milestones, further positioning us to become a fully integrated biopharmaceutical company,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “As cemsidomide progresses into later-stage clinical trials across multiple lines of therapy in multiple myeloma, we believe it is well positioned to become the IKZF1/3 degrader of choice. We continue to advance our discovery strategy, focused on targets that have a strong degrader rationale with first-in-class potential in inflammation, neuroinflammation and neurodegeneration diseases. Together, these achievements will bring us closer to delivering transformative TPD medicines for patients with significant unmet needs.” FOURTH QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS In February 2026, the first patient was dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in the fourth line or later MM setting. The MOMENTUM trial was designed for potential accelerated approval with a recommended Phase 2 dose of 100 µg. The trial will enroll approximately 100 patients with enrollment expected to be completed in Q1 2027. In October 2025, C4T entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the...

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide in Combination With Elranatamab On Track to Initiate Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 MOMENTUM Trial in Combination with Dexamethasone in Q1 2026 and Phase 1b Trial in Combination with Elranatamab in Q2 2026 WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the third quarter ended September 30, 2025, as well as business updates. “Recent months have been transformative for C4T, and we are in a strong position to rapidly advance cemsidomide registrational development and progress our discovery pipeline of degraders against non-oncology and oncology targets,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We remain laser-focused on initiating cemsidomide’s next phase of development in early 2026, which includes a Phase 1b trial in combination with elranatamab as well as the Phase 2 MOMENTUM trial in combination with dexamethasone, which has potential for accelerated approval. With a successful raise of $125 million in upfront proceeds, we have extended our runway to the end of 2028, beyond important data from cemsidomide’s Phase 2 trial with dexamethasone and the Phase 1b in combination with elranatamab, strengthening our balance sheet to continue to deliver on the promise of targeted protein degradation to improve patients’ lives.” THIRD QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS Clinical: Presented Phase 1 data of cemsidomide in combination with dexamethasone in multiple myeloma (MM) demonstrating a potential best-in-class profile in a heavily pre-treated patient population and supports cemsidomide’s advancement to a Phase 1b trial in combination with elranatamab and a Phase 2 MOMENTUM (Multi-...

Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is Focused on Two Projects Within the KRAS Family Disciplined Capital Allocation Extends Runway to Mid-2027 WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the second quarter ended June 30, 2025, as well as business updates. “The first half of 2025 was driven by focused execution across our business with the achievement of several research milestones with our collaborators and within our internal preclinical pipeline, the advancement of cemsidomide toward label-enabling trials and continued financial discipline that resulted in extending cash runway. We recently completed enrollment in the ongoing cemsidomide Phase 1 trials in multiple myeloma and non-Hodgkin’s lymphoma and look forward to sharing the full Phase 1 multiple myeloma data in September, which we believe further demonstrate cemsidomide’s best-in-class potential. Our recent Type C meeting with the FDA enabled refinement of our cemsidomide registrational development plans and we remain on track to initiate registrational development in early 2026,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Additionally, as part of C4T’s commitment to strategic capital allocation and despite cemsidomide’s compelling response rates observed in non-Hodgkin’s lymphoma, we are prioritizing cemsidomide multiple myeloma registrational development as we believe this has the highest potential for patient impact and value creation.” SECOND QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS Cemsidomide: Completed enrollment and dose escalation for the Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s Lymphoma (NHL). Cemsidomide continued to demonstrate a well-tolerated profile and compelling respo...

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 Portfolio Decision to Prioritize Cemsidomide Development; C4T to Seek Partnership Opportunities to Advance BRAF Program CFT8919 Phase 1 Trial Continues to Advance in Partnership with Betta Pharmaceuticals; Discovery Platform Achieves Two Preclinical Milestones Under the Roche Collaboration Cash, Cash Equivalents and Marketable Securities of $234.7 Million as of March 31, 2025 Expected to Provide Runway Into 2027 WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2025, as well as business updates. “2025 has been marked by focused execution across C4T to generate key data to optimize development plans across our clinical portfolio. With cemsidomide demonstrating compelling overall response rates at multiple dose levels, including one multiple myeloma patient at 100 µg who achieved a minimal residual disease negative complete response, we are prioritizing progressing cemsidomide to the next phase of development to realize its potential to be a best-in-class IKZF1/3 degrader,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “With the achievement of two preclinical milestones in our Roche collaboration, we continue to demonstrate the productivity of our TORPEDO platform to discover highly catalytic, orally bioavailable, and brain penetrant degraders. We remain focused on maximizing our cash runway, which includes advancing cemsidomide and pursuing our internal discovery pipeline focused on targets with a clear degrader rationale and compelling biology applicable to a broad range of therapeutic areas.” FIRST QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS Cemsidomide: Phase 1 dose escalation is complete in multiple myeloma (MM) with the 100 µg...